QSP/QST Modeling Support for NASH Drug Development

Authors: Siler SQ
Keywords: drug development, NASH, Non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), QSP (quantitative systems pharmacology) modeling program
Software: DILIsym®, NAFLDsym®
Division: DILIsym Services

Quantitative Systems Pharmacology (QSP) Supports Clinical Development by Emphasizing Mechanistic Understanding of Pathophysiology and Treatment

  • The complex, interconnected pathophysiology of many diseases poses challenges to developing effective treatments
  • QSP models, such as NAFLDsym, help enhance the understanding of the disease pathophysiology and its treatment
  • Reduce knowledge gaps
  • Ability to predict response to combination treatments
  • QSP models provide the ability to predict responses to treatments while accounting for inter-patient variability as well as mechanistic feedback loops
  • QSP models can provide ability to predict disease progression

By Scott Siler

Leveraging Clinical Pharmacology to Optimize Drug Development for Nonalcoholic Steatohepatitis (NASH) and Cholestatic Liver Diseases at Duke Margolis Center in collaboration with the U.S. Food and Drug Administration (FDA) on December 9, 2019